Lakewood-Amedex Inc. to Present at 2018 BIO CEO & Investor Conference

SARASOTA, Fla., February 8, 2018 – Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, today announced that it will present at the 2018 BIO CEO & Investor Conference, held February 12-13, 2018, in New York City.

Steve Parkinson, President and CEO of Lakewood-Amedex, plans to present data on the Company’s lead therapeutic candidate, Nu-3, a topically applied antimicrobial which recently completed a Phase 1/2a clinical trial in patients with infected diabetic foot ulcers (iDFU). The presentation will also highlight the Company’s second drug candidate, Nu-8, which Lakewood-Amedex anticipates advancing into preclinical IND-enabling studies following positive pre-IND written communications with the FDA. Nu-8 will be developed for the treatment of complicated urinary tract infections (cUTI) that are currently treated with systemic orally delivered antibiotics.

Lakewood-Amedex Presentation Details:
Date: Tuesday, February 13, 2018
Time: 9:45 AM (Eastern Time)
Location: New York Marriott Marquis, Gilbert Room


About Lakewood-Amedex Inc.
Lakewood-Amedex is a clinical stage pharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class antimicrobial compounds. The Company’s products and technology are covered by an extensive patent portfolio consisting of over 60 granted and/or issued patents and 6 pending patent applications covering many major pharmaceutical markets. The Company’s lead therapeutic candidate is a novel synthetic broad-spectrum antimicrobial proven to be effective in killing a wide range of Gram-positive, Gram-negative and antibiotic-resistant bacteria and has recently completed a Phase 1/2a clinical trial in patients with infected diabetic foot ulcers (iDFU).

Tiberend Strategic Advisors, Inc.
Jonathon Brzezinski, Ph.D. (investors)
(212) 375-2681

Tiberend Strategic Advisors, Inc.
David Schemelia (media)
(212) 375-2686